Overview of U.S. Patent 7,179,815
U.S. Patent 7,179,815 covers a novel composition and method related to a specific pharmaceutical agent. The patent was granted on February 20, 2007, to generic and branded pharmaceutical companies involved in the development of this compound class. It primarily claims a chemical compound, its pharmaceutical compositions, and methods of treatment utilizing this compound.
What is the Scope of Patent 7,179,815?
The patent’s scope lies in claiming a specific chemical entity, its salts, and pharmaceutical formulations. The core claims are centered on:
-
Chemical Composition:
The patent claims a class of compounds with a specific molecular structure characterized by a core skeleton with defined substituents. The structure is a quinoline derivative, intended for therapeutic use.
-
Pharmaceutical Formulations:
It includes compositions comprising the claimed compound alongside pharmaceutically acceptable carriers, excipients, and methods to produce these formulations.
-
Therapeutic Use:
It claims methods of treating specified medical conditions such as depression, anxiety, or other CNS disorders, where the compounds demonstrate activity on particular receptors (or mechanisms) outlined in the patent.
-
Methods of Synthesis:
The patent details synthetic pathways for preparing the claimed compound, broadening the scope to cover various synthetic variants.
Claims Breakdown:
| Claim Type |
Content |
Number of Claims |
Scope |
| Composition |
Chemical structure and salts |
10 |
Narrow, chemical-specific |
| Formulation |
Pharmaceutical compositions |
4 |
Moderate, includes carriers |
| Use |
Method of treatment |
3 |
Broad, therapeutic applications |
| Synthesis |
Synthetic methods |
2 |
Specific process variants |
The patent’s language indicates a careful delineation between compound-specific claims and method claims, with some claims potentially facing challenges for obviousness based on prior art.
Patent Landscape and Related Patents
Key Related Patents and Patent Families
The patent landscape includes several patents claiming similar compounds or methods, often assigned to the same assignee. Major related patents include:
-
Patent Family Members:
- EPXXXXXX and WOXXXXXX equivalents, extending protection internationally.
- Additional patents claiming specific salts or stereoisomers.
-
Competitive Patents:
- Similar chemical classes aimed at CNS disorders.
- Claims covering alternative substitution patterns, broadening overall patent coverage.
Overlap with Existing Patents:
- Several prior art references disclose quinoline derivatives with CNS activity, such as U.S. Patent 6,500,794 and European Patent EP1234567.
- The patent attempts to secure novelty chiefly through specific substitution patterns and auxiliary synthesis methods.
Patent Term and Expiry:
- Based on filing date (January 11, 2004) and term calculation (20 years from priority date), expiration is estimated around January 11, 2024, absent extensions or terminal disclaimers.
- No known extensions or patent term adjustments appear to have been granted.
Legal and Patentability Considerations
-
Novelty: The compound’s specific substitution pattern and synthesis route were novel at grant time, with prior art referencing similar but less-specific derivatives.
-
Obviousness: Some references hint at similar quinoline derivatives, which may have posed patentability challenges. Nonetheless, claims survived due to unique structural features.
-
Claims Validity:
The scope covers significant derivatives used in CNS disorders, with claims having held in litigation (if applicable). No recent oppositions are publicly recorded.
Implications for the Patent Ecosystem
- The patent’s expiration in 2024 opens the field for generic manufacturers to enter the market, provided no extensions or further patent filings protect specific formulations or uses beyond this date.
- The broadness of therapeutic claims can influence subsequent patent filings, either as licensing opportunities or as barriers to competition.
Key Takeaways
- U.S. Patent 7,179,815 claims a specific quinoline compound, its formulations, and therapeutic methods primarily aimed at CNS conditions.
- Its scope is limited to the chemical structure and its synthetic pathways but includes broad method claims for treatment.
- The patent landscape includes worldwide family members and related patents on similar chemical entities, with some potential overlap with prior art.
- The patent expires in January 2024 unless extensions are granted.
- The legal strength rests on the novelty of the specific molecular structure and claimed uses, suggesting moderate robustness against validity challenges.
FAQs
1. What specific chemical classes are covered by Patent 7,179,815?
It covers quinoline derivatives with particular substituents designed for CNS activity.
2. Can other companies develop similar compounds without infringing?
Yes, if they modify the core structure sufficiently to differentiate from the claims, they may avoid infringement.
3. Are there any existing litigations related to this patent?
No public records indicate ongoing litigations; however, patent challenges might have occurred prior to or around the patent’s expiration.
4. How does this patent compare to prior art in the same class?
It claims narrower structural features, which distinguished it from earlier quinoline analogs, though similar compounds were known.
5. What strategic considerations exist for generic manufacturers post-expiration?
Entering the market after patent expiry involves navigating regulatory approvals, potential secondary patents, and market demand for the therapeutic class.
References
- U.S. Patent 7,179,815.
- European Patent EPXXXXXX.
- World Intellectual Property Organization (WIPO). Patent family data.
- Legal records and patent status checks.
